Skip to main content
. 2020 Jul 14;7:138. doi: 10.3389/fcvm.2020.00138

Table 1.

Baseline participant characteristics.

COVID-19 tested (n = 7,099) COVID-19 positive (n = 1,439) COVID-19 negative (n = 5,660) Untested population (n = 494,838)
Sex (Male) 3,525 (49.7%) 761 (52.9%) 2,764 (48.8%) 225,352 (45.5%)
Age* 69.11 (±8.65) 68.22 (±9.19) 69.34 (±8.49) 68.24 (±8.10)
White ethnicity 6,498 (91.5%) 1,242 (86.3%) 5,256 (92.9%) 465,681 (94.1%)
BAME ethnicity 562 (7.9%) 185 (12.9%) 377 (6.7%) 26,429 (5.3%)
BMI (kg/m2) 27.66 [24.78, 31.13] 27.97 [25.18, 31.50] 27.58 [24.69, 31.02] 26.7 [±24.13, 29.89]
Smoking** 3,663 (51.6%) 732 (50.9%) 2,931 (51.8%) 221,478 (44.8%)
Prior MI 557 (7.8%) 103 (7.2%) 454 (8.0%) 20,227 (4.1%)
Diabetes 1,029 (14.5%) 241 (16.7%) 788 (13.9%) 38,046 (7.7%)
Hypertension 3,338 (47.0%) 676 (47.0%) 2,662 (47.0%) 171,415 (34.6%)
High cholesterol 2,388 (33.6%) 477 (33.1%) 1,911 (33.8%) 115,133 (23.3%)
ACEi 1,117 (15.7%) 227 (15.8%) 890 (15.7%) 50,635 (10.2%)
ARB 418 (5.9%) 87 (6.0%) 331 (5.8%) 20,416 (4.1%)

Data are n (%), mean (standard deviation), or median [interquartile range]. COVID-19 data includes test results from 16/03/2020 to 14/06/2020 from hospital settings.

*

We report age of participants as of 01/04/2020.

**

Smoking includes current and previous smoking.

ACEi/ARB use is defined as a binary measure, defined as true if record of any of medications in Supplementary Table 2. ACEi, Angiotensin Converting Enzyme inhibitor; ARB, Angiotensin Receptor Blocker; BAME, Black, Asian, and Minority ethnic; BMI, body mass index; COVID-19, coronavirus 2019.